Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients With Recent Diagnosis of HIV-1 Infection

[1]  Jeffrey N. Martin,et al.  Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy , 2010, Journal of acquired immune deficiency syndromes.

[2]  W. Heneine,et al.  Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.–2006 , 2010, AIDS.

[3]  C. Charpentier,et al.  High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors , 2010, AIDS.

[4]  A. Lazzarin,et al.  Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience , 2010, AIDS.

[5]  F. Baldanti,et al.  Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. , 2010, The Journal of antimicrobial chemotherapy.

[6]  C. Katlama,et al.  High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. John,et al.  Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance , 2009, Antiviral Therapy.

[8]  Adriano Lazzarin,et al.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial , 2009, The Lancet.

[9]  D. Hazuda,et al.  Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors , 2009, Antimicrobial Agents and Chemotherapy.

[10]  S. L. Teixeira,et al.  Lack of Primary Mutations Associated With Integrase Inhibitors Among HIV-1 Subtypes B, C, and F Circulating in Brazil , 2009, Journal of acquired immune deficiency syndromes.

[11]  K. Hertogs,et al.  Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors , 2008, Journal of Virology.

[12]  D. Hazuda,et al.  Raltegravir with optimized background therapy for resistant HIV-1 infection. , 2008, The New England journal of medicine.

[13]  R. Di Santo,et al.  HIV type 1 integrase inhibitors: from basic research to clinical implications. , 2008, AIDS reviews.

[14]  Edward P Acosta,et al.  Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. , 2008, The Journal of infectious diseases.

[15]  M. Matsuoka,et al.  Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137) , 2007, Journal of Virology.

[16]  K. Borroto-Esoda,et al.  Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. , 2007, AIDS research and human retroviruses.

[17]  M. Kozal,et al.  Natural Polymorphism of the HIV-1 Integrase Gene and Mutations associated with Integrase Inhibitor Resistance , 2007, Antiviral therapy.

[18]  B. Masquelier,et al.  Primary Resistance to Enfuvirtide (T20) in recently HIV-1 Infected, Antiretroviral-Naive Patients from the ANRS Aquitaine Cohort , 2007, Antiviral therapy.

[19]  B. Gazzard,et al.  Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis , 2006, Journal of acquired immune deficiency syndromes.

[20]  D. Pillay,et al.  The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy , 2006, AIDS.

[21]  D. Pillay,et al.  Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study , 2005, BMJ : British Medical Journal.

[22]  Klaus Korn,et al.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.

[23]  L. Pérez-Alvárez,et al.  Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[24]  A. Lazzarin,et al.  Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment , 2004, Antimicrobial Agents and Chemotherapy.

[25]  D. Hazuda,et al.  Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques , 2004, Science.

[26]  A. Telenti,et al.  Infrequent Transmission of HIV-1 Drug-Resistant Variants , 2003, Antiviral therapy.

[27]  Simon D W Frost,et al.  Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. , 2003, The Journal of infectious diseases.

[28]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.